Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 255

1.

The molecular landscape of the University of Michigan laryngeal squamous cell carcinoma cell line panel.

Mann JE, Kulkarni A, Birkeland AC, Kafelghazal J, Eisenberg J, Jewell BM, Ludwig ML, Spector ME, Jiang H, Carey TE, Brenner JC.

Head Neck. 2019 May 15. doi: 10.1002/hed.25803. [Epub ahead of print]

PMID:
31090975
2.

Multisite HPV infections in the United States (NHANES 2003-2014): An overview and synthesis.

Brouwer AF, Eisenberg MC, Carey TE, Meza R.

Prev Med. 2019 Jun;123:288-298. doi: 10.1016/j.ypmed.2019.03.040. Epub 2019 Apr 5.

PMID:
30959071
3.

Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.

Michmerhuizen NL, Leonard E, Matovina C, Harris M, Herbst G, Kulkarni A, Zhai J, Jiang H, Carey TE, Brenner JC.

Mol Pharmacol. 2019 May;95(5):528-536. doi: 10.1124/mol.118.115162. Epub 2019 Mar 11.

PMID:
30858165
4.

Impact of American Joint Committee on Cancer Eighth Edition clinical stage and smoking history on oncologic outcomes in human papillomavirus-associated oropharyngeal squamous cell carcinoma.

Hawkins PG, Mierzwa ML, Bellile E, Jackson WC, Malloy KM, Chinn SB, Spector ME, Shuman AG, Stucken CL, McLean SA, Bradford CR, Prince ME, Carey TE, Worden FP, Swiecicki PL, Taylor JMG, Wolf GT, Eisbruch A, Casper KA.

Head Neck. 2019 Apr;41(4):857-864. doi: 10.1002/hed.25336. Epub 2019 Feb 18.

PMID:
30775826
5.

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.

Citro S, Bellini A, Miccolo C, Ghiani L, Carey TE, Chiocca S.

Br J Cancer. 2019 Mar;120(6):658-667. doi: 10.1038/s41416-019-0394-9. Epub 2019 Feb 15.

PMID:
30765872
6.

Promoter methylation of galanin receptors as epigenetic biomarkers for head and neck squamous cell carcinomas.

Kanazawa T, Misawa K, Shinmura K, Misawa Y, Kusaka G, Maruta M, Sasaki T, Watanabe Y, Carey TE.

Expert Rev Mol Diagn. 2019 Feb;19(2):137-148. doi: 10.1080/14737159.2019.1567334. Epub 2019 Jan 21.

PMID:
30640567
7.

The genomic landscape of UM-SCC oral cavity squamous cell carcinoma cell lines.

Ludwig ML, Kulkarni A, Birkeland AC, Michmerhuizen NL, Foltin SK, Mann JE, Hoesli RC, Devenport SN, Jewell BM, Shuman AG, Spector ME, Carey TE, Jiang H, Brenner JC.

Oral Oncol. 2018 Dec;87:144-151. doi: 10.1016/j.oraloncology.2018.10.031. Epub 2018 Nov 8.

PMID:
30527230
8.

Genomic and Transcriptomic Characterization Links Cell Lines with Aggressive Head and Neck Cancers.

Cheng H, Yang X, Si H, Saleh AD, Xiao W, Coupar J, Gollin SM, Ferris RL, Issaeva N, Yarbrough WG, Prince ME, Carey TE, Van Waes C, Chen Z.

Cell Rep. 2018 Oct 30;25(5):1332-1345.e5. doi: 10.1016/j.celrep.2018.10.007.

9.

Analysis of tumor-infiltrating CD103 resident memory T-cell content in recurrent laryngeal squamous cell carcinoma.

Mann JE, Smith JD, Birkeland AC, Bellile E, Swiecicki P, Mierzwa M, Chinn SB, Shuman AG, Malloy KM, Casper KA, McLean SA, Moyer JS, Wolf GT, Bradford CR, Prince ME, Carey TE, McHugh JB, Spector ME, Brenner JC.

Cancer Immunol Immunother. 2019 Feb;68(2):213-220. doi: 10.1007/s00262-018-2256-3. Epub 2018 Oct 25.

PMID:
30361882
10.

Characterization of hemostasis in mice lacking the novel thrombosis susceptibility gene Slc44a2.

Tilburg J, Adili R, Nair TS, Hawley ME, Tuk DC, Jackson M, Spronk HM, Versteeg HH, Carey TE, van Vlijmen BJM, Maracle CX, Holinstat M.

Thromb Res. 2018 Nov;171:155-159. doi: 10.1016/j.thromres.2018.09.057. Epub 2018 Sep 26.

PMID:
30312801
11.

Dynamics and Determinants of HPV Infection: The Michigan HPV and Oropharyngeal Cancer (M-HOC) Study.

Eisenberg MC, Campredon LP, Brouwer AF, Walline HM, Marinelli BM, Lau YK, Thomas TB, Delinger RL, Sullivan TS, Yost ML, Goudsmit CM, Carey TE, Meza R.

BMJ Open. 2018 Oct 2;8(10):e021618. doi: 10.1136/bmjopen-2018-021618.

12.

Comprehensive Genomic Profiling of Patient-matched Head and Neck Cancer Cells: A Preclinical Pipeline for Metastatic and Recurrent Disease.

Nisa L, Barras D, Medová M, Aebersold DM, Medo M, Poliaková M, Koch J, Bojaxhiu B, Eliçin O, Dettmer MS, Angelino P, Giger R, Borner U, Caversaccio MD, Carey TE, Ho L, McKee TA, Delorenzi M, Zimmer Y.

Mol Cancer Res. 2018 Dec;16(12):1912-1926. doi: 10.1158/1541-7786.MCR-18-0056. Epub 2018 Aug 14.

PMID:
30108165
13.

DNA concentration from self samples for HPV testing.

Meza R, Lau YK, Thomas TB, Carey TE, Walline HM, Eisenberg MC.

Int J Cancer. 2018 Dec 1;143(11):3036-3037. doi: 10.1002/ijc.31666. Epub 2018 Oct 3. No abstract available.

PMID:
29978468
14.

Epigenetic inactivation of galanin receptors in salivary duct carcinoma of the parotid gland: Potential utility as biomarkers for prognosis.

Kanazawa T, Misawa K, Fukushima H, Misawa Y, Sato Y, Maruta M, Imayoshi S, Kusaka G, Kawabata K, Mineta H, Carey TE, Nishino H.

Oncol Lett. 2018 Jun;15(6):9043-9050. doi: 10.3892/ol.2018.8525. Epub 2018 Apr 18.

15.

Mitigating SOX2-potentiated Immune Escape of Head and Neck Squamous Cell Carcinoma with a STING-inducing Nanosatellite Vaccine.

Tan YS, Sansanaphongpricha K, Xie Y, Donnelly CR, Luo X, Heath BR, Zhao X, Bellile E, Hu H, Chen H, Polverini PJ, Chen Q, Young S, Carey TE, Nör JE, Ferris RL, Wolf GT, Sun D, Lei YL.

Clin Cancer Res. 2018 Sep 1;24(17):4242-4255. doi: 10.1158/1078-0432.CCR-17-2807. Epub 2018 May 16.

PMID:
29769207
16.

Retraction notice to: Sensitization of squamous cell carcinoma to cisplatin induced killing by natural agents.

Ali S, Varghese L, Pereira L, Tulunay-Ugur OE, Kucuk O, Carey TE, Wolf GT, Sarkar FH.

Cancer Lett. 2018 Jun 1;423:154. doi: 10.1016/j.canlet.2018.03.018.

17.

HLA class I antigen processing machinery (APM) component expression and PD-1:PD-L1 pathway activation in HIV-infected head and neck cancers.

Pai SI, Jack Lee J, Carey TE, Westra WH, Ferrone S, Moore C, Mosunjac MB, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Oral Oncol. 2018 Feb;77:92-97. doi: 10.1016/j.oraloncology.2017.12.014. Epub 2017 Dec 28.

18.

Human Papillomavirus Genome Integration and Head and Neck Cancer.

Pinatti LM, Walline HM, Carey TE.

J Dent Res. 2018 Jun;97(6):691-700. doi: 10.1177/0022034517744213. Epub 2017 Dec 11.

19.

Human papillomavirus (HPV) and somatic EGFR mutations are essential, mutually exclusive oncogenic mechanisms for inverted sinonasal papillomas and associated sinonasal squamous cell carcinomas.

Udager AM, McHugh JB, Goudsmit CM, Weigelin HC, Lim MS, Elenitoba-Johnson KSJ, Betz BL, Carey TE, Brown NA.

Ann Oncol. 2018 Feb 1;29(2):466-471. doi: 10.1093/annonc/mdx736.

20.

Novel C-Terminal Heat Shock Protein 90 Inhibitors (KU711 and Ku757) Are Effective in Targeting Head and Neck Squamous Cell Carcinoma Cancer Stem cells.

Subramanian C, Kovatch KJ, Sim MW, Wang G, Prince ME, Carey TE, Davis R, Blagg BSJ, Cohen MS.

Neoplasia. 2017 Dec;19(12):1003-1011. doi: 10.1016/j.neo.2017.09.003. Epub 2017 Nov 6.

21.

Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.

Gleber-Netto FO, Zhao M, Trivedi S, Wang J, Jasser S, McDowell C, Kadara H, Zhang J, Wang J, William WN Jr, Lee JJ, Nguyen ML, Pai SI, Walline HM, Shin DM, Ferris RL, Carey TE, Myers JN, Pickering CR; Head and Neck Cancer Specialized Program of Research Excellence (SPORE) Human Immunodeficiency Virus (HIV) Supplement Consortium.

Cancer. 2018 Jan 1;124(1):84-94. doi: 10.1002/cncr.31063. Epub 2017 Oct 20.

22.

An Algorithm to Evaluate Suspected Lung Metastases in Patients with HPV-Associated Oropharyngeal Cancer.

VanKoevering KK, Marchiano E, Walline HM, Carey TE, McHugh JB, Brenner JC, Goudsmit CM, Belille E, Spector ME, Shuman AG; University of Michigan Head and Neck SPORE Team.

Otolaryngol Head Neck Surg. 2018 Jan;158(1):118-121. doi: 10.1177/0194599817733677. Epub 2017 Sep 26.

23.

Prognostic biomarkers in patients with human immunodeficiency virus-positive disease with head and neck squamous cell carcinoma.

Zhang H, Kim S, Chen Z, Nannapaneni S, Chen AY, Moore CE, Sica G, Mosunjac M, Nguyen MLT, D'Souza G, Carey TE, Peterson LA, McHugh JB, Graham M, Komarck CM, Wolf GT, Walline HM, Bellile E, Riddell J 4th, Pai SI, Sidransky D, Westra WH, William WN Jr, Lee JJ, El-Naggar AK, Ferris RL, Seethala R, Grandis JR, Chen ZG, Saba NF, Shin DM; Head and Neck Cancer SPORE HIV supplement consortium.

Head Neck. 2017 Dec;39(12):2433-2443. doi: 10.1002/hed.24911. Epub 2017 Sep 25.

24.

HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers.

Koneva LA, Zhang Y, Virani S, Hall PB, McHugh JB, Chepeha DB, Wolf GT, Carey TE, Rozek LS, Sartor MA.

Mol Cancer Res. 2018 Jan;16(1):90-102. doi: 10.1158/1541-7786.MCR-17-0153. Epub 2017 Sep 19.

25.

Epigenetic silencing of SALL3 is an independent predictor of poor survival in head and neck cancer.

Misawa K, Mochizuki D, Imai A, Misawa Y, Endo S, Mima M, Kawasaki H, Carey TE, Kanazawa T.

Clin Epigenetics. 2017 Jun 12;9:64. doi: 10.1186/s13148-017-0363-1. eCollection 2017.

26.

Correlation of Crtc1/3-Maml2 fusion status, grade and survival in mucoepidermoid carcinoma.

Birkeland AC, Foltin SK, Michmerhuizen NL, Hoesli RC, Rosko AJ, Byrd S, Yanik M, Nor JE, Bradford CR, Prince ME, Carey TE, McHugh JB, Spector ME, Brenner JC.

Oral Oncol. 2017 May;68:5-8. doi: 10.1016/j.oraloncology.2017.02.025. Epub 2017 Mar 10.

27.

Immortal Life of the Common Rule: Ethics, Consent, and the Future of Cancer Research.

Smith JD, Birkeland AC, Goldman EB, Brenner JC, Carey TE, Spector-Bagdady K, Shuman AG.

J Clin Oncol. 2017 Jun 10;35(17):1879-1883. doi: 10.1200/JCO.2016.68.4522. Epub 2017 Apr 20. No abstract available. Erratum in: J Clin Oncol. 2017 Dec 20;35(36):4096.

28.

Integration of high-risk human papillomavirus into cellular cancer-related genes in head and neck cancer cell lines.

Walline HM, Goudsmit CM, McHugh JB, Tang AL, Owen JH, Teh BT, McKean E, Glover TW, Graham MP, Prince ME, Chepeha DB, Chinn SB, Ferris RL, Gollin SM, Hoffmann TK, Bier H, Brakenhoff R, Bradford CR, Carey TE; University of Michigan Head and Neck Specialized Program of Research Excellence (SPORE) Program.

Head Neck. 2017 May;39(5):840-852. doi: 10.1002/hed.24729. Epub 2017 Feb 25.

29.

Minichromosome maintenance protein 7 and geminin expression: Prognostic value in laryngeal squamous cell carcinoma in patients treated with radiotherapy and cetuximab.

Almadori G, Lauriola L, Coli A, Bussu F, Gallus R, Scannone D, Valentini V, Paludetti G, Carey TE, Ranelletti FO.

Head Neck. 2017 Apr;39(4):684-693. doi: 10.1002/hed.24670. Epub 2016 Dec 29.

30.

High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV.

Walline HM, Carey TE, Goudsmit CM, Bellile EL, D'Souza G, Peterson LA, McHugh JB, Pai SI, Lee JJ, Shin DM, Ferris RL; HNC SPORE HIV supplement consortium.

Mol Cancer Res. 2017 Feb;15(2):179-188. doi: 10.1158/1541-7786.MCR-16-0255. Epub 2016 Nov 29.

31.

STAT3 Inhibition as a Therapeutic Strategy for Chordoma.

Wang AC, Owen JH, Abuzeid WM, Hervey-Jumper SL, He X, Gurrea M, Lin M, Altshuler DB, Keep RF, Prince ME, Carey TE, Fan X, McKean EL, Sullivan SE.

J Neurol Surg B Skull Base. 2016 Dec;77(6):510-520. Epub 2016 May 31.

32.

SLC44A2 single nucleotide polymorphisms, isoforms, and expression: Association with severity of Meniere's disease?

Nair TS, Kommareddi PK, Galano MM, Miller DM, Kakaraparthi BN, Telian SA, Arts HA, El-Kashlan H, Kilijanczyk A, Lassig AA, Graham MP, Fisher SG, Stoll SW, Nair RP, Elder JT, Carey TE.

Genomics. 2016 Dec;108(5-6):201-208. doi: 10.1016/j.ygeno.2016.11.002. Epub 2016 Nov 6.

33.

Site-specific methylation patterns of the GAL and GALR1/2 genes in head and neck cancer: Potential utility as biomarkers for prognosis.

Misawa K, Mochizuki D, Endo S, Mima M, Misawa Y, Imai A, Shinmura K, Kanazawa T, Carey TE, Mineta H.

Mol Carcinog. 2017 Mar;56(3):1107-1116. doi: 10.1002/mc.22577. Epub 2016 Nov 1.

34.

Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma.

Walline HM, Komarck CM, McHugh JB, Bellile EL, Brenner JC, Prince ME, McKean EL, Chepeha DB, Wolf GT, Worden FP, Bradford CR, Carey TE.

Mol Cancer Res. 2016 Oct;14(10):941-952. Epub 2016 Jul 15.

35.

Classification of TP53 mutations and HPV predict survival in advanced larynx cancer.

Scheel A, Bellile E, McHugh JB, Walline HM, Prince ME, Urba S, Wolf GT, Eisbruch A, Worden F, Carey TE, Bradford C.

Laryngoscope. 2016 Sep;126(9):E292-9. doi: 10.1002/lary.25915. Epub 2016 Jun 27.

36.

A phase II trial of the BCL-2 homolog domain 3 mimetic AT-101 in combination with docetaxel for recurrent, locally advanced, or metastatic head and neck cancer.

Swiecicki PL, Bellile E, Sacco AG, Pearson AT, Taylor JM, Jackson TL, Chepeha DB, Spector ME, Shuman A, Malloy K, Moyer J, McKean E, McLean S, Sukari A, Wolf GT, Eisbruch A, Prince M, Bradford C, Carey TE, Wang S, Nör JE, Worden FP.

Invest New Drugs. 2016 Aug;34(4):481-9. doi: 10.1007/s10637-016-0364-5. Epub 2016 May 26.

37.

In vivo Wnt pathway inhibition of human squamous cell carcinoma growth and metastasis in the chick chorioallantoic model.

Rudy SF, Brenner JC, Harris JL, Liu J, Che J, Scott MV, Owen JH, Komarck CM, Graham MP, Bellile EL, Bradford CR, Prince ME, Carey TE.

J Otolaryngol Head Neck Surg. 2016 Apr 26;45:26. doi: 10.1186/s40463-016-0140-8.

38.

Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures.

Zhang Y, Koneva LA, Virani S, Arthur AE, Virani A, Hall PB, Warden CD, Carey TE, Chepeha DB, Prince ME, McHugh JB, Wolf GT, Rozek LS, Sartor MA.

Clin Cancer Res. 2016 Sep 15;22(18):4735-45. doi: 10.1158/1078-0432.CCR-16-0323. Epub 2016 Apr 18.

39.

Identification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.

Birkeland AC, Yanik M, Tillman BN, Scott MV, Foltin SK, Mann JE, Michmerhuizen NL, Ludwig ML, Sandelski MM, Komarck CM, Carey TE, Prince ME, Bradford CR, McHugh JB, Spector ME, Brenner JC.

JAMA Otolaryngol Head Neck Surg. 2016 Jun 1;142(6):559-67. doi: 10.1001/jamaoto.2016.0335.

40.

Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer.

Misawa K, Mochizuki D, Imai A, Endo S, Mima M, Misawa Y, Kanazawa T, Carey TE, Mineta H.

Oncotarget. 2016 May 3;7(18):26087-98. doi: 10.18632/oncotarget.8317.

41.

Exploration for an Algorithm for Deintensification to Exclude the Retropharyngeal Site From Advanced Oropharyngeal Squamous Cell Carcinoma Treatment.

Spector ME, Chinn SB, Bellile E, Gallagher KK, Kang SY, Moyer JS, Prince ME, Wolf GT, Bradford CR, McHugh JB, Carey TE, Worden FP, Eisbruch A, Ibrahim M, Chepeha DB.

JAMA Otolaryngol Head Neck Surg. 2016 Apr;142(4):313-8. doi: 10.1001/jamaoto.2015.3602.

42.

Tumor infiltrating lymphocytes and survival in patients with head and neck squamous cell carcinoma.

Nguyen N, Bellile E, Thomas D, McHugh J, Rozek L, Virani S, Peterson L, Carey TE, Walline H, Moyer J, Spector M, Perim D, Prince M, McLean S, Bradford CR, Taylor JM, Wolf GT; Head and Neck SPORE Program Investigators.

Head Neck. 2016 Jul;38(7):1074-84. doi: 10.1002/hed.24406. Epub 2016 Feb 16.

43.

Fibroblast growth factor family aberrations as a putative driver of head and neck squamous cell carcinoma in an epidemiologically low-risk patient as defined by targeted sequencing.

Tillman BN, Yanik M, Birkeland AC, Liu CJ, Hovelson DH, Cani AK, Palanisamy N, Carskadon S, Carey TE, Bradford CR, Tomlins SA, McHugh JB, Spector ME, Brenner JCh.

Head Neck. 2016 Apr;38 Suppl 1:E1646-52. doi: 10.1002/hed.24292. Epub 2016 Feb 5.

44.

Effects of peritumoral nanoconjugated cisplatin on laryngeal cancer stem cells.

Sim MW, Grogan PT, Subramanian C, Bradford CR, Carey TE, Forrest ML, Prince ME, Cohen MS.

Laryngoscope. 2016 May;126(5):E184-90. doi: 10.1002/lary.25808. Epub 2015 Dec 21.

45.

Trends in HPV cervical and seroprevalence and associations between oral and genital infection and serum antibodies in NHANES 2003-2012.

Brouwer AF, Eisenberg MC, Carey TE, Meza R.

BMC Infect Dis. 2015 Dec 21;15:575. doi: 10.1186/s12879-015-1314-0.

46.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

47.

Epigenetic inactivation of galanin and GALR1/2 is associated with early recurrence in head and neck cancer.

Misawa K, Misawa Y, Kanazawa T, Mochizuki D, Imai A, Endo S, Carey TE, Mineta H.

Clin Exp Metastasis. 2016 Feb;33(2):187-95. doi: 10.1007/s10585-015-9768-4. Epub 2015 Nov 16.

PMID:
26572146
48.

NDN and CD1A are novel prognostic methylation markers in patients with head and neck squamous carcinomas.

Virani S, Bellile E, Bradford CR, Carey TE, Chepeha DB, Colacino JA, Helman JI, McHugh JB, Peterson LA, Sartor MA, Taylor JM, Walline HM, Wolf GT, Rozek LS.

BMC Cancer. 2015 Oct 30;15:825. doi: 10.1186/s12885-015-1806-8.

49.

Hair Cell Loss, Spiral Ganglion Degeneration, and Progressive Sensorineural Hearing Loss in Mice with Targeted Deletion of Slc44a2/Ctl2.

Kommareddi P, Nair T, Kakaraparthi BN, Galano MM, Miller D, Laczkovich I, Thomas T, Lu L, Rule K, Kabara L, Kanicki A, Hughes ED, Jones JM, Hoenerhoff M, Fisher SG, Altschuler RA, Dolan D, Kohrman DC, Saunders TL, Carey TE.

J Assoc Res Otolaryngol. 2015 Dec;16(6):695-712.

50.

G-Protein-Coupled Receptors: Next Generation Therapeutic Targets in Head and Neck Cancer?

Kanazawa T, Misawa K, Misawa Y, Uehara T, Fukushima H, Kusaka G, Maruta M, Carey TE.

Toxins (Basel). 2015 Aug 5;7(8):2959-84. doi: 10.3390/toxins7082959. Review.

Supplemental Content

Loading ...
Support Center